China pharmaceutical maker CanSino rallies in Hong Kong and Shanghai trading after Covid-19 vaccine gets WHO approval

The move opens a door for the company’s one-dose Convidecia vaccine to enter the global market

CanSino shares slid at least 79 per cent over the past year amid increased competition and falling vaccine prices in China

Reading Time:2 minutes

CanSino Biologics’ building in Tianjin, China. Photo: Reuters

Published: 3:19pm, 20 May 2022Updated: 4:20pm, 20 May 2022

CanSino Biologics jumped in Hong Kong and Shanghai trading after the World Health Organization (WHO) approved its Covid-19 vaccine for emergency use, opening a door for the product to enter the global market.

Hong Kong-listed shares of CanSino surged nearly 10 per cent to HK$77.95 in trading Friday, the biggest gain since March, while its Shanghai-traded stocks rose 12 per cent to 164.40 yuan at Friday’s close, the best one-day performance since April last year.

Tianjin-based CanSino is the third Chinese company to make it to WHO’s emergency-use list after Sinopharm and Sinovac Biotech, which got the endorsement last year. Its one-dose Convidecia vaccine has 64 per cent efficacy against symptomatic Covid-19 infections and 92 per cent efficacy against severe cases, and is recommended for use among people aged 18 or above, according to WHO.

CanSino shares have slid at least 79 per cent over the past year in Hong Kong and Shanghai as rising vaccination rates in China led to falling prices for Covid-19 vaccines. About 91 per cent of China’s population was vaccinated by the end of April, with 87 per cent fully vaccinated, according to official data.

CanSino Biologics’ Convidecia has 64 per cent efficacy against symptomatic Covid-19 infections and 92 per cent efficacy against severe cases. Photo: Shutterstock

The endorsement is a global acknowledgement of CanSino’s Covid-19 vaccine and will be conducive to its overseas expansion, according to Essence Securities.